Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.
Reardon DA, et al. Among authors: friedman hs, friedman ah.
J Clin Oncol. 2006 Jan 1;24(1):115-22. doi: 10.1200/JCO.2005.03.4082.
J Clin Oncol. 2006.
PMID: 16382120
Clinical Trial.